Lateral	B-LF
flow	B-O
devices	B-O
.	B-O
Using	B-O
these	B-O
data,	B-O
we	B-O
determined	B-O
that,	B-O
at	B-O
100	B-O
viral	B-O
copies	B-O
per	B-O
ml	B-O
.	B-O
Ct,	B-O
cycle	B-O
threshold;	B-O
RT-PCR,	B-O
reverse	B-LF
transcription	I-LF
PCR;	B-O
SARS-CoV-2,	B-O
Severe	B-LF
Acute	I-LF
Respiratory	I-LF
Syndrome	I-LF
Coronavirus	I-LF
2.	B-O
Download:	B-O
PPT	B-O
PowerPoint	B-O
slide	B-O
PNG	B-O
larger	B-O
image	B-O
TIFF	B-O
original	B-O
image	B-O
Table	B-O
2.	B-O
Pillar	B-O
2	I-LF
PCR	I-LF
Ct	B-O
values	B-O
of	I-LF
confirmatory	B-O
samples	B-O
positive	B-O
for	B-O
SARS-CoV-2.	B-O
The	B-O
samples	B-O
which	B-O
tested	B-O
positive	B-O
on	B-O
Lateral	B-LF
Flow	I-LF
device	B-O
are	B-O
in	B-O
grey	B-O
columns.	B-O
Sensitivity	B-O
of	I-LF
lateral	B-O
flow	B-O
device	B-O
in	B-O
the	B-O
student	B-O
population	B-O
by	B-O
Ct	B-O
value	B-O
From	B-O
our	B-O
data,	B-O
the	B-O
LFD	B-AC
test	B-O
yield	B-O
is	B-O
2.8	B-O
per	B-O
10,000	B-O
.	B-O
Using	B-O
the	B-O
LoD	B-AC
of	I-LF
100	B-O
pfu/ml,	B-O
we	B-O
determined	B-O
that	B-O
this	B-O
would	B-O
correlate	B-O
with	B-O
an	B-O
N	B-O
gene	B-O
Ct	B-O
value	B-O
of	I-LF
30.8	B-O
plus	B-O
one	B-O
other	B-O
gene	B-O
target	B-O
amplifying	B-O
at	B-O
a	B-O
Ct	B-O
<35.	B-O
By	B-O
applying	B-O
this	B-O
theoretical	B-O
level	B-O
of	I-LF
performance	B-O
to	B-O
the	B-O
LFD,	B-O
we	B-O
determine	B-O
that	B-O
99	B-O
of	I-LF
our	B-O
positive	B-O
samples	B-O
would	B-O
not	B-O
be	B-O
able	B-O
to	B-O
be	B-O
detected	B-O
by	B-O
the	B-O
Innova	B-O
LFD	B-AC
given	B-O
that	B-O
the	B-O
Ct	B-O
value	B-O
of	I-LF
N	B-O
gene	B-O
is	B-O
above	B-O
30.8.	B-O
This	B-O
equates	B-O
to	B-O
15.44%	B-O
of	I-LF
our	B-O
true	B-O
positive	B-O
RT-PCR	B-AC
samples	B-O
would	B-O
not	B-O
be	B-O
detected	B-O
using	B-O
the	B-O
Innova	B-O
LFD.	B-O
This	B-O
means	B-O
that,	B-O
theoretically,	B-O
the	B-O
Innova	B-O
LFD	B-AC
for	B-O
all	B-O
641	B-O
positive	B-O
samples	B-O
in	B-O
the	B-O
Birmingham	B-O
Turnkey	B-O
lab	B-O
(y-axis).	B-O
Ct	B-O
values	B-O
for	B-O
each	B-O
of	I-LF
the	B-O
targets	B-O
(Orf1,	B-O
N,	B-O
S)	B-O
are	B-O
plotted,	B-O
with	B-O
a	B-O
sample	B-O
only	B-O
called	B-O
positive	B-O
if	B-O
at	B-O
least	B-O
2	I-LF
of	I-LF
the	B-O
3	B-O
targets	B-O
have	B-O
a	B-O
Ct	B-O
<35.	B-O
The	B-O
red	B-O
line	B-O
indicates	B-O
the	B-O
N	B-O
gene	B-O
Ct	B-O
value	B-O
equating	B-O
to	B-O
100	B-O
viral	B-O
copies/ml,	B-O
the	B-O
previously	B-O
determined	B-O
LoD	B-AC
for	B-O
the	B-O
Innova	B-O
LFD.	B-O
Ct,	B-O
cycle	B-O
threshold;	B-O
LFD,	B-O
Lateral	B-LF
Flow	I-LF
Device;	B-O
LoD,	B-O
Limit	B-LF
of	I-LF
Detection.	B-O
Discussion	B-O
Expansion	B-O
of	I-LF
mass	B-O
testing	B-O
for	B-O
SARS-CoV-2	B-AC
is	B-O
an	B-O
issue	B-O
many	B-O
countries	B-O
are	B-O
facing,	B-O
with	B-O
LFDs	B-O
seen	B-O
as	B-O
a	B-O
viable	B-O
accompaniment	B-O
to	B-O
the	B-O
gold	B-O
standard	B-O
of	I-LF
RT-PCR	B-AC
tests	B-O
as	B-O
a	B-O
way	B-O
to	B-O
increase	B-O
capacity	B-O
and	B-O
screen	B-O
asymptomatic	B-O
populations.	B-O
The	B-O
University	B-O
of	I-LF
Birmingham	B-O
deployed	B-O
a	B-O
purpose	B-O
built	B-O
testing	B-O
facility	B-O
in	B-O
order	B-O
to	B-O
screen	B-O
its	B-O
student	B-O
population	B-O
before	B-O
they	B-O
travelled	B-O
home	B-O
in	B-O
the	B-O
lead	B-O
up	B-O
to	B-O
the	B-O
2020	B-O
holiday	B-O
period.	B-O
A	B-O
total	B-O
of	I-LF
7,183	B-O
students	B-O
were	B-O
tested	B-O
over	B-O
an	B-O
8-day	B-O
period,	B-O
with	B-O
2	I-LF
positive	B-O
tests;	B-O
a	B-O
prevalence	B-O
of	I-LF
0.03%	B-O
(95%	B-O
CI	B-AC
0.02%	B-O
to	B-O
0.10%).	B-O
Approximately	B-O
10%	B-O
of	I-LF
tests	B-O
carried	B-O
out	B-O
across	B-O
the	B-O
study	B-O
were	B-O
sent	B-O
to	B-O
an	B-O
onsite	B-O
Pillar	B-O
2	I-LF
testing	B-O
lab	B-O
(termed	B-O
Turnkey)	B-O
for	B-O
RT-PCR	B-AC
validation.	B-O
The	B-O
validation,	B-O
carried	B-O
out	B-O
using	B-O
the	B-O
ThermoFisher	B-O
COVID-19	B-AC
TaqPath	B-O
assay,	B-O
confirmed	B-O
the	B-O
2	I-LF
positive	B-O
LFD	B-AC
results.	B-O
This	B-O
gave	B-O
a	B-O
false	B-O
positive	B-O
rate	B-O
of	I-LF
rate	B-O
0%,	B-O
therefore	B-O
indicating	B-O
a	B-O
100%	B-O
(95%	B-O
CI	B-AC
99.48%	B-O
to	B-O
100.00%)	B-O
specificity	B-O
of	I-LF
the	B-O
test	B-O
in	B-O
this	B-O
study.	B-O
The	B-O
high	B-O
specificity	B-O
rate	B-O
suggests	B-O
that	B-O
what	B-O
we	B-O
are	B-O
seeing	B-O
are	B-O
true	B-O
positive	B-O
samples,	B-O
and	B-O
this	B-O
is	B-O
exemplified	B-O
in	B-O
the	B-O
recent	B-O
report	B-O
published	B-O
by	B-O
the	B-O
DHSC	B-AC
suggesting	B-O
an	B-O
LFD	B-AC
specificity	B-O
rate	B-O
of	I-LF
99.72%	B-O
.	B-O
There	B-O
has	B-O
been	B-O
some	B-O
controversy	B-O
over	B-O
sensitivity	B-O
and	B-O
specificity	B-O
of	I-LF
the	B-O
Innova	B-O
LFD	B-AC
platform	B-O
[	B-O
13	B-O
,	B-O
14	B-O
].	B-O
Importantly,	B-O
the	B-O
studies	B-O
that	B-O
are	B-O
often	B-O
cited	B-O
in	B-O
such	B-O
controversies	B-O
relied	B-O
on	B-O
RT-PCR	B-AC
analysis	B-O
of	I-LF
a	B-O
swab	B-O
taken	B-O
on	B-O
a	B-O
separate	B-O
day,	B-O
whereas	B-O
our	B-O
study	B-O
analysed	B-O
the	B-O
same	B-O
prepared	B-O
sample	B-O
that	B-O
provided	B-O
a	B-O
positive	B-O
LFD	B-AC
result.	B-O
Swabbing	B-O
technique	B-O
can	B-O
largely	B-O
impact	B-O
the	B-O
accuracy	B-O
of	I-LF
diagnostic	B-O
platforms;	B-O
research	B-O
shows	B-O
that	B-O
the	B-O
accuracy	B-O
of	I-LF
RT-PCR	B-AC
testing	B-O
is	B-O
significantly	B-O
increased	B-O
when	B-O
the	B-O
swab	B-O
is	B-O
taken	B-O
by	B-O
a	B-O
trained	B-O
scientist	B-O
(79%)	B-O
when	B-O
compared	B-O
to	B-O
swabs	B-O
taken	B-O
by	B-O
members	B-O
of	I-LF
the	B-O
public	B-O
(58%)	B-O
.	B-O
As	B-O
such,	B-O
a	B-O
large	B-O
part	B-O
of	I-LF
the	B-O
variation	B-O
in	B-O
sensitivity	B-O
and	B-O
specificity	B-O
rates	B-O
may	B-O
be	B-O
confounded	B-O
by	B-O
differences	B-O
in	B-O
swabbing	B-O
technique,	B-O
rather	B-O
than	B-O
by	B-O
the	B-O
technical	B-O
limitations	B-O
of	I-LF
the	B-O
Innova	B-O
LFD	B-AC
platform	B-O
itself.	B-O
From	B-O
a	B-O
public	B-O
health	B-O
perspective,	B-O
our	B-O
positive	B-O
sample	B-O
size	B-O
was	B-O
thankfully	B-O
small;	B-O
however,	B-O
for	B-O
a	B-O
true	B-O
validation	B-O
of	I-LF
false	B-O
positivity,	B-O
an	B-O
ideal	B-O
dataset	B-O
would	B-O
include	B-O
many	B-O
more	B-O
positive	B-O
samples	B-O
and,	B-O
importantly,	B-O
rely	B-O
on	B-O
a	B-O
single	B-O
swab	B-O
to	B-O
reduce	B-O
variation.	B-O
By	B-O
screening	B-O
samples	B-O
that	B-O
were	B-O
deemed	B-O
negative	B-O
by	B-O
LFD,	B-O
RT-PCR	B-AC
validation	B-O
detected	B-O
6	B-O
samples	B-O
that	B-O
were	B-O
determined	B-O
to	B-O
be	B-O
false	B-O
negatives	B-O
(	B-O
Table	B-O
1	B-O
).	B-O
This	B-O
suggests	B-O
a	B-O
true	B-O
prevalence	B-O
of	I-LF
0.86%	B-O
(95%	B-O
CI	B-AC
0.40%	B-O
to	B-O
1.86%)	B-O
within	B-O
the	B-O
cohort	B-O
tested	B-O
and	B-O
when	B-O
extrapolating	B-O
from	B-O
these	B-O
data,	B-O
represents	B-O
60	B-O
potentially	B-O
missed	B-O
positive	B-O
cases.	B-O
Using	B-O
this	B-O
information,	B-O
we	B-O
explored	B-O
the	B-O
LOD	B-O
for	B-O
LFDs.	B-O
Given	B-O
the	B-O
barriers	B-O
to	B-O
culturing	B-O
SARS-CoV-2,	B-O
we	B-O
did	B-O
not	B-O
determine	B-O
a	B-O
viral	B-O
titre	B-O
for	B-O
these	B-O
samples;	B-O
however,	B-O
we	B-O
correlated	B-O
N	B-O
gene	B-O
Ct	B-O
values	B-O
with	B-O
viral	B-O
titre	B-O
by	B-O
using	B-O
the	B-O
Qnostics	B-O
SARS-CoV-2	B-AC
analytical	B-O
Q-panel.	B-O
This	B-O
validated	B-O
the	B-O
limit	B-O
of	I-LF
detection	B-O
of	I-LF
Innova	B-O
LFD	B-AC
devices	B-O
as	B-O
100	B-O
pfu/ml,	B-O
which	B-O
correlated	B-O
to	B-O
an	B-O
N	B-O
gene	B-O
Ct	B-O
value	B-O
of	I-LF
approximately	B-O
30.	B-O
Unfortunately,	B-O
the	B-O
Qnostics	B-O
panel	B-O
contains	B-O
irradiated	B-O
virus	B-O
which	B-O
as	B-O
a	B-O
result	B-O
cannot	B-O
be	B-O
detected	B-O
on	B-O
the	B-O
Innova	B-O
LFD,	B-O
meaning	B-O
a	B-O
cross	B-O
validation	B-O
of	I-LF
the	B-O
LoD	B-AC
could	B-O
not	B-O
be	B-O
performed	B-O
on	B-O
matching	B-O
material;	B-O
however,	B-O
our	B-O
data	B-O
are	B-O
concordant	B-O
with	B-O
larger-scale	B-O
studies	B-O
which	B-O
have	B-O
comparatively	B-O
reported	B-O
the	B-O
LoD	B-AC
of	I-LF
the	B-O
Innova	B-O
test	B-O
[	B-O
7	B-O
,	B-O
15	B-O
,	B-O
16	B-O
].	B-O
Importantly,	B-O
all	B-O
of	I-LF
the	B-O
false	B-O
negative	B-O
samples	B-O
had	B-O
N	B-O
gene	B-O
Cts	B-O
above	B-O
or	B-O
close	B-O
to	B-O
30	B-O
and	B-O
therefore	B-O
above	B-O
or	B-O
close	B-O
to	B-O
the	B-O
limit	B-O
of	I-LF
detection	B-O
for	B-O
the	B-O
Innova	B-O
LFDs.	B-O
These	B-O
may	B-O
be	B-O
representative	B-O
of	I-LF
individuals	B-O
at	B-O
the	B-O
very	B-O
early	B-O
or	B-O
very	B-O
late	B-O
stages	B-O
of	I-LF
infection,	B-O
who	B-O
may	B-O
have	B-O
a	B-O
relatively	B-O
lower	B-O
titre	B-O
of	I-LF
SARS-CoV-2	B-AC
in	B-O
the	B-O
swabbed	B-O
sites	B-O
at	B-O
the	B-O
time	B-O
the	B-O
swab	B-O
was	B-O
taken.	B-O
It	B-O
is	B-O
therefore	B-O
imperative	B-O
that	B-O
individuals	B-O
undergo	B-O
regular,	B-O
routine	B-O
testing,	B-O
to	B-O
accurately	B-O
remove	B-O
infected	B-O
individuals	B-O
from	B-O
community	B-O
transmission	B-O
pools.	B-O
First	B-O
reports	B-O
of	I-LF
variants	B-O
of	I-LF
concern	B-O
(VOCs)	B-O
were	B-O
published	B-O
following	B-O
the	B-O
closure	B-O
of	I-LF
this	B-O
test	B-O
site	B-O
in	B-O
December;	B-O
however,	B-O
the	B-O
UK	B-O
VOC	B-O
(also	B-O
referred	B-O
to	B-O
as	B-O
the	B-O
Kent	B-O
VOC)	B-O
was	B-O
known	B-O
to	B-O
be	B-O
circulating	B-O
in	B-O
late	B-O
September	B-O
.	B-O
Since	B-O
then,	B-O
numerous	B-O
other	B-O
VOCs	B-AC
have	B-O
been	B-O
identified	B-O
through	B-O
genomic	B-O
sequencing	B-O
of	I-LF
positive	B-O
cases	B-O
worldwide;	B-O
most	B-O
notably	B-O
with	B-O
in	B-O
the	B-O
UK	B-O
with	B-O
COVID-19	B-AC
Genomics	B-O
UK	B-O
Consortium	B-O
(COG-UK)	B-O
.	B-O
While	B-O
this	B-O
study	B-O
did	B-O
not	B-O
look	B-O
at	B-O
VOCs	B-AC
specifically,	B-O
research	B-O
carried	B-O
out	B-O
by	B-O
PHE	B-O
showed	B-O
that	B-O
the	B-O
Innova	B-O
LFD	B-AC
platform	B-O
could	B-O
detect	B-O
the	B-O
UK	B-O
VOC	B-O
.	B-O
Recent	B-O
emergence	B-O
of	I-LF
the	B-O
South	B-O
African	B-O
VOC	B-O
can	B-O
also	B-O
be	B-O
detected	B-O
on	B-O
this	B-O
platform	B-O
.	B-O
With	B-O
these	B-O
datasets	B-O
in	B-O
mind,	B-O
we	B-O
would	B-O
suggest	B-O
that	B-O
both	B-O
the	B-O
UK	B-O
and	B-O
South	B-O
African	B-O
VOCs	B-AC
can	B-O
be	B-O
reliably	B-O
detected	B-O
using	B-O
the	B-O
Innova	B-O
LFD	B-AC
platform	B-O
but	B-O
as	B-O
more	B-O
variants	B-O
emerge,	B-O
these	B-O
will	B-O
require	B-O
their	B-O
own	B-O
rapid	B-O
evaluation	B-O
by	B-O
relevant	B-O
public	B-O
health	B-O
bodies	B-O
in	B-O
their	B-O
respective	B-O
countries.	B-O
The	B-O
caveat	B-O
to	B-O
this	B-O
is	B-O
whether	B-O
the	B-O
comparative	B-O
Ct	B-O
values	B-O
and	B-O
LOD	B-O
are	B-O
the	B-O
same	B-O
for	B-O
SARS-CoV-2	B-AC
variants	B-O
as	B-O
they	B-O
are	B-O
with	B-O
the	B-O
wild	B-O
type,	B-O
something	B-O
out	B-O
of	I-LF
scope	B-O
in	B-O
this	B-O
project.	B-O
Short	B-O
of	I-LF
national	B-O
restrictions,	B-O
control	B-O
of	I-LF
case	B-O
numbers	B-O
within	B-O
a	B-O
population	B-O
relies	B-O
heavily	B-O
on	B-O
diagnostic	B-O
testing	B-O
capacity.	B-O
Multipronged	B-O
approaches	B-O
to	B-O
mass	B-O
testing	B-O
using	B-O
a	B-O
suite	B-O
of	I-LF
platforms	B-O
including	B-O
LFDs	B-O
will	B-O
be	B-O
a	B-O
huge	B-O
benefit	B-O
to	B-O
public	B-O
health	B-O
and	B-O
SARS-CoV-2	B-AC
surveillance,	B-O
provided	B-O
the	B-O
tests	B-O
are	B-O
deployed	B-O
correctly	B-O
and	B-O
that	B-O
public	B-O
health	B-O
messaging	B-O
is	B-O
clear	B-O
and	B-O
accurate.	B-O
The	B-O
Innova	B-O
LFD	B-AC
device	B-O
should	B-O
“not”	B-O
be	B-O
considered	B-O
as	B-O
a	B-O
green-light	B-O
test—that	B-O
is	B-O
to	B-O
say	B-O
that	B-O
a	B-O
result	B-O
from	B-O
an	B-O
LFD	B-AC
should	B-O
not	B-O
allow	B-O
individuals	B-O
to	B-O
participate	B-O
in	B-O
an	B-O
activity	B-O
that	B-O
they	B-O
would	B-O
otherwise	B-O
not	B-O
participate	B-O
in,	B-O
if	B-O
their	B-O
infective	B-O
status	B-O
was	B-O
not	B-O
known.	B-O
The	B-O
LFD	B-AC
device	B-O
can	B-O
provide	B-O
an	B-O
individual	B-O
with	B-O
an	B-O
idea	B-O
of	I-LF
their	B-O
colonisation	B-O
state	B-O
“at	B-O
that	B-O
time,”	B-O
but	B-O
as	B-O
shown	B-O
by	B-O
the	B-O
limit	B-O
of	I-LF
detection,	B-O
individuals	B-O
with	B-O
a	B-O
low	B-O
associated	B-O
N	B-O
gene	B-O
Ct	B-O
(e.g.,	B-O
people	B-O
at	B-O
the	B-O
start	B-O
or	B-O
end	B-O
of	I-LF
an	B-O
infection)	B-O
may	B-O
test	B-O
negative.	B-O
However,	B-O
when	B-O
used	B-O
regularly,	B-O
in	B-O
the	B-O
correct	B-O
red-light	B-O
fashion,	B-O
LFDs	B-O
can	B-O
be	B-O
a	B-O
highly	B-O
effective	B-O
tool	B-O
in	B-O
reducing	B-O
overall	B-O
community	B-O
burden,	B-O
with	B-O
a	B-O
particular	B-O
benefit	B-O
to	B-O
places	B-O
of	I-LF
work	B-O
and	B-O
study	B-O
and	B-O
any	B-O
other	B-O
venues	B-O
that	B-O
would	B-O
have	B-O
a	B-O
relatively	B-O
high	B-O
proportion	B-O
of	I-LF
attendance	B-O
despite	B-O
potential	B-O
COVID-secure	B-O
restrictions.	B-O
Conclusions	B-O
Our	B-O
data	B-O
show	B-O
that	B-O
the	B-O
Innova	B-O
LFD	B-AC
can	B-O
successfully	B-O
detect	B-O
SARS-CoV-2	B-AC
infection	B-O
in	B-O
people	B-O
with	B-O
a	B-O
viral	B-O
titre	B-O
above	B-O
approximately	B-O
100	B-O
viral	B-O
copies/ml.	B-O
However,	B-O
as	B-O
determined	B-O
at	B-O
our	B-O
site	B-O
using	B-O
the	B-O
ThermoFisher	B-O
COVID-19	B-AC
TaqPath	B-O
assay,	B-O
it	B-O
is	B-O
incapable	B-O
of	I-LF
detecting	B-O
infection	B-O
at	B-O
comparable	B-O
PCR	I-LF
Ct	B-O
values	B-O
of	I-LF
30	B-O
and	B-O
over.	B-O
These	B-O
levels	B-O
of	I-LF
infection	B-O
are	B-O
indicative	B-O
of	I-LF
very	B-O
early	B-O
or	B-O
very	B-O
late	B-O
stages	B-O
of	I-LF
infection,	B-O
and	B-O
as	B-O
such,	B-O
we	B-O
would	B-O
strongly	B-O
recommend	B-O
that	B-O
LFD	B-AC
testing	B-O
is	B-O
used	B-O
to	B-O
screen	B-O
people	B-O
at	B-O
very	B-O
regular	B-O
frequency	B-O
and	B-O
that	B-O
a	B-O
negative	B-O
result	B-O
should	B-O
not	B-O
be	B-O
used	B-O
to	B-O
determine	B-O
that	B-O
someone	B-O
is	B-O
free	B-O
from	B-O
SARS-CoV-2	B-AC
infection.	B-O
Supporting	B-O
information	B-O
Raw	B-O
PCR	I-LF
Ct	B-O
values	B-O
for	B-O
all	B-O
SARS-CoV-2–positive	B-O
samples	B-O
analysed	B-O
in	B-O
the	B-O
University	B-O
of	I-LF
Birmingham	B-O
Pillar	B-O
2	I-LF
testing	B-O
lab	B-O
between	B-O
October	B-O
1	B-O
and	B-O
November	B-O
5,	B-O
2020.	B-O
Skip	B-O
to	B-O
fig	B-O
share	B-O
navigation	B-O
Sheet	B-O
1	B-O
Share	B-O
Download	B-O
fig	B-O
share	B-O
S1	B-O
Table.	B-O
Raw	B-O
PCR	I-LF
Ct	B-O
values	B-O
for	B-O
all	B-O
SARS-CoV-2–positive	B-O
samples	B-O
analysed	B-O
in	B-O
the	B-O
University	B-O
of	I-LF
Birmingham	B-O
Pillar	B-O
2	I-LF
testing	B-O
lab	B-O
between	B-O
October	B-O
1	B-O
and	B-O
November	B-O
5,	B-O
2020.	B-O
(XLSX)	B-O
